Evidence mapPaperPMID 39440721Full record

ArticleInternal medicine journal2024

Development and validation of a predictive scoring system for hypoglycaemic agents for optimal control of blood glucose during glucocorticoid therapy.

Ayaka Kato, Masayuki Fuwa, Motochika Asano, Ichiro Mori, Saori Iida, Hideyuki Okada, Yoshihiro Uno, Kei Fujioka, Hiroyuki Morita

Abstract readValidation Study
In one paragraph

Article in Internal medicine journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ayaka KatoDepartment of General Medicine and General Internal Medicine, Gifu University Graduate School of Medicine, Gifu, Japan.ORCID 0009-0009-2148-8475
Masayuki FuwaDepartment of General Medicine and General Internal Medicine, Gifu University Graduate School of Medicine, Gifu, Japan.
Motochika AsanoDepartment of General Medicine and General Internal Medicine, Gifu University Graduate School of Medicine, Gifu, Japan.
Ichiro MoriDepartment of General Medicine and General Internal Medicine, Gifu University Graduate School of Medicine, Gifu, Japan.
Saori IidaDepartment of General Internal Medicine, Gifu Prefectural General Medical Center, Gifu, Japan.
Hideyuki OkadaDepartment of General Internal Medicine, Gifu Prefectural General Medical Center, Gifu, Japan.
Yoshihiro UnoDepartment of General Internal Medicine, Gifu Prefectural General Medical Center, Gifu, Japan.
Kei FujiokaCenter of General Internal Medicine and Rheumatology, Gifu Municipal Hospital, Gifu, Japan.
Hiroyuki MoritaDepartment of General Medicine and General Internal Medicine, Gifu University Graduate School of Medicine, Gifu, Japan.ORCID 0000-0003-0256-251X

Funding

Japan Society for the Promotion of Science 23K06864
6 · The paper itself

Abstract

backgroundGlucocorticoid (GC) treatments are often used. There is limited information on the prediction of hyperglycaemia after GC administration.

aimsThis study aimed to identify the risk factors for hyperglycaemia after glucocorticoid (GC) administration and the need for hypoglycaemic agents to correct it and to develop and validate a novel scoring system for predicting GC-induced hyperglycaemia.

methodsIn a development set, 508 adults receiving prednisolone (PSL) for the first time were divided into two groups based on treatment with or without hypoglycaemic agents. Clinical and laboratory parameters were compared, and risk factors were identified using logistic regression analysis after performing univariate analyses between the two groups. A point-addition scoring system with several categories and coefficients for each risk factor was constructed to predict the need for hypoglycaemic agents. The scoring system was then applied and validated on two validation sets: A and B.

resultsOlder age, higher glycated haemoglobin percentage, body mass index and initial PSL dosage were identified as risk factors. The sensitivity, specificity and accuracy of the scoring system were 70.6%, 81.9% and 77.1% in the development set; 75.8%, 78.4% and 77.4% in validation set A; and 79.4%, 73.9% and 75.3% in validation set B respectively. By fitting the total score in the development set and the probability of hyperglycaemia to a logistic curve, a figure was created to show the probability of GC-induced hyperglycaemia in patients scheduled to receive GC.

conclusionThis scoring system is a novel, valid and reliable tool for predicting GC-induced hyperglycaemia and the need for hypoglycaemic agents to correct it.

Indexed as

Blood GlucoseGlucocorticoidsHyperglycemiaHypoglycemic AgentsPrednisoloneAdultAgedFemaleGlycated HemoglobinHumansMaleMiddle AgedPredictive Value of TestsRetrospective StudiesRisk FactorsBlood GlucoseGlucocorticoidsGlycated HemoglobinHypoglycemic AgentsPrednisoloneglucocorticoid‐induced hyperglycaemiahypoglycaemic agentsprednisolonerisk factorsscoring system

Identifiers

PMID39440721
PMCPMC11610689

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.